Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer
Launched by NATIONAL CANCER INSTITUTE (NCI) · Nov 14, 2019
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is examining whether adding an anti-cancer drug called pembrolizumab to the standard chemotherapy treatment, gemcitabine, can help patients with non-muscle invasive bladder cancer whose disease has not improved after receiving Bacillus Calmette-Guerin (BCG) therapy. The goal is to see if this combination can keep the cancer from coming back for a longer time compared to using gemcitabine alone.
To be eligible for this trial, participants should be adults aged 18 and older who have specific types of bladder cancer that haven't responded to BCG treatment. They must also have had their cancer surgically removed within the last couple of months. Participants can expect to receive both pembrolizumab and gemcitabine during the trial, and they will be monitored closely for any side effects and changes in their condition. It's important for interested patients to discuss with their doctor whether they meet the criteria and to understand the potential risks and benefits of joining the study.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • High grade Ta, T1 or CIS urothelial carcinoma. Accrual of patients with Ta or T1 disease may be closed to ensure adequate patients enrollment to meet the primary endpoint
- • Persistent disease (defined as not achieving disease free status) after completing therapy with at least induction BCG (\>= 5 doses) and the first round of maintenance or second induction course (\>= 2 doses). The subsequent round of BCG, either maintenance or repeat induction, must be given within 6 months of initial induction BCG
- • Persistent high risk NMIBC (T1, high grade Ta and/or CIS) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above.
- • Registration must be within 12 months of last BCG instillation
- • High grade T1 after completing therapy with at least induction BCG (\>= 5 doses) or after completing therapy with at least induction BCG (\>= 5 doses) and first round of maintenance or second induction course (\>= 2 doses). The subsequent round of BCG, either maintenance or repeat induction, must be given within 6 months of initial induction BCG
- • Disease recurrence (T1) must be within 9 months of the last BCG instillation despite having received adequate BCG as defined above
- • Registration must be within 12 months of last BCG instillation
- • Mixed variant histology (adenocarcinoma, squamous cell carcinoma) is eligible, but pure variant histology is ineligible
- • Patients who are disease free at 6 months after starting BCG but have high grade recurrence (T1, Ta, CIS) while on maintenance therapy would be eligible
- • The recurrence must be within 6 months of the last BCG dose.
- • Registration must be within 12 months of last maintenance BCG instillation
- • Patients must be deemed unfit for radical cystectomy by the treating physician or refuse radical cystectomy
- • All patients must have histologically confirmed urothelial cancer of the bladder within 60 days prior to registration
- • All visible tumor must be completely resected 60 days prior to registration (residual pure CIS is permitted)
- • All patients must have had a cystoscopy (or TURBT with complete resection) without papillary tumor and negative urinary cytology within 28 days of registration (positive cytology is allowed in patients with CIS)
- • All patients with T1 tumors must undergo a re-staging transurethral resection of bladder tumor (TURBT) within 60 days of registration
- • There must be uninvolved muscularis propria present in the re-staging TURBT. The initial TURBT prior to re-staging TURBT may be greater than 60 days prior to registration
- • Patients must have had imaging with CT or MRI abdomen/pelvis within 90 days of registration demonstrating no evidence of metastasis
- • Patients cannot have had a history of urothelial carcinoma in the ureters or prostatic urethra 24 months prior to registration
- • Patients must not be currently participating in or have participated in a study of an investigational agent or have used an investigational device within 4 weeks prior to study registration
- • Note: Participants who have entered the follow-up phase of an investigational study may participate as long as it has been more than 4 weeks after the last dose of the previous investigational agent at time of registration
- • Patients must not have prior therapy with an anti-PD-1, anti-PD-L1, or anti PD L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g., CTLA-4, OX 40, CD137)
- • Patients must not have undergone prior allogeneic hematopoietic stem cell transplantation within the last 5 years prior to registration. (Participants who have had a transplant greater than 5 years ago are eligible as long as there are no symptoms of graft versus host disease \[GVHD\])
- • Patients must not have received prior systemic anti-cancer therapy including investigational agents within 4 weeks prior to treatment
- • Note: Participants must have recovered from all adverse events (AEs) due to previous therapies to =\< grade 1 or baseline. Participants with =\< grade 2 neuropathy may be eligible
- • Note: If participant received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting study treatment
- • Patients must not have received prior radiotherapy within 2 weeks of study registration. Participants must have recovered from all radiation-related toxicities, not require corticosteroids, and not have had radiation pneumonitis
- • Patients must not have received radiation therapy to the lung that is \> 30 Gy within 6 months prior to trial registration
- • Not pregnant and not nursing, because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects
- • Women and men of reproductive potential should agree to use an appropriate method of birth control throughout their participation in this study due to the teratogenic potential of the therapy utilized in this trial. Include as applicable: Appropriate methods of birth control include abstinence, oral contraceptives, implantable hormonal contraceptives or double barrier method (diaphragm plus condom)
- • A woman of childbearing potential (WOCBP) must not have a positive urine pregnancy test within 7 days prior to registration. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required
- • Patients must not be pregnant or breastfeeding or expecting to conceive or father children within the projected duration of the study, starting with registration through the last dose of treatment
- • Age \>= 18 years
- • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- • Absolute neutrophil count (ANC) \>= 1,500/mm\^3
- • Platelet count \>= 100,000/mm\^3
- • Hemoglobin \>= 9.0 g/dL
- • Creatinine =\< 1.5 x upper limit of normal (ULN)
- • In patients with creatinine \> 1.5 x ULN, if measured or calculated creatinine clearance \> 30 mL/min, then patient is eligible
- • Total bilirubin =\< 1.5 x ULN
- • In patients with a total bilirubin \> 1.5 x ULN, if direct bilirubin \< 1.0 X ULN, then patient is eligible
- • Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) =\< 2.5 x ULN
- • Patients must not have had an active autoimmune disease requiring systemic treatment within 24 months prior to registration. Autoimmune diseases include, but not limited to, lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, or glomerulonephritis
- • Patients must not have a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to registration
- • Note: Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed
- • Patients must not have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study
- • Patients must not have active tuberculosis
- • Patients must not have been treated with antibiotics for an active infection within 14 days prior to registration. Prophylactic antibiotics are permitted. Treatment for a urinary tract infection (UTI) is allowed but must be deemed adequately treated by the treating physician prior the start of cycle 1 (C1) day 1 (D1)
- • Patients must not have a history of idiopathic pulmonary fibrosis or organizing pneumonia
- • Patients must not have a history of (non-infectious) pneumonitis that required steroids or have current pneumonitis
- * Patients with human immunodeficiency virus (HIV) are eligible with the following:
- • On effective anti-retroviral therapy with undetectable viral load within 6 months of registration
- • HIV-infected participants must not have a history of Kaposi sarcoma and/or multicentric Castleman disease
- • Patients must not have a known additional malignancy that has had progression or has required active treatment in the last three years. Exceptions include basal or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer. A history of prostate cancer that was treated with definitive intent is allowed, provided that the prostate-specific antigen (PSA) is undetectable for at least 1 year while off androgen deprivation therapy
- • Patients must not have known active CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, i.e., without evidence of progression for at least 4 weeks by repeat imaging (note that the repeat imaging should be performed during study screening), clinically stable and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment
- • Patients must not have severe hypersensitivity (\>= grade 3) to pembrolizumab and/or any of its excipients
- • Patients must not have an active infection requiring systemic therapy
- • Patients must not have a known history of hepatitis B (defined as hepatitis B surface antigen \[HBsAg\] reactive) or known active hepatitis C virus (defined as hepatitis C virus \[HCV\] ribonucleic acid \[RNA\] \[qualitative\] is detected) infection
- • Note: No testing for hepatitis B and hepatitis C is required unless mandated by a local health authority
- • Patients must not have received live vaccines within 30 days of study drug administration. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. COVID-19 vaccinations are permitted
About National Cancer Institute (Nci)
The National Cancer Institute (NCI) is a prominent component of the National Institutes of Health (NIH), dedicated to advancing cancer research and improving patient outcomes through innovative clinical trials. As a leading sponsor of cancer-related studies, NCI focuses on facilitating the development of new therapies, enhancing prevention strategies, and understanding the biology of cancer. The institute collaborates with academic institutions, healthcare providers, and industry partners to conduct rigorous clinical trials that aim to translate scientific discoveries into effective treatments. NCI’s commitment to fostering a robust research environment supports the mission to eliminate cancer as a major health problem.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lebanon, New Hampshire, United States
Milwaukee, Wisconsin, United States
New York, New York, United States
Flint, Michigan, United States
Denver, Colorado, United States
Lone Tree, Colorado, United States
Flint, Michigan, United States
Kalamazoo, Michigan, United States
Burnsville, Minnesota, United States
Edina, Minnesota, United States
Waconia, Minnesota, United States
Maywood, Illinois, United States
Peoria, Illinois, United States
South Bend, Indiana, United States
Baton Rouge, Louisiana, United States
Salt Lake City, Utah, United States
Galveston, Texas, United States
Anchorage, Alaska, United States
Hackensack, New Jersey, United States
Oklahoma City, Oklahoma, United States
Great Falls, Montana, United States
Ridgewood, New Jersey, United States
Saint Paul, Minnesota, United States
Greeley, Colorado, United States
Loveland, Colorado, United States
Kalamazoo, Michigan, United States
Traverse City, Michigan, United States
Bozeman, Montana, United States
Kalispell, Montana, United States
Logan, Utah, United States
Ogden, Utah, United States
Sheridan, Wyoming, United States
Chicago, Illinois, United States
Mount Vernon, Illinois, United States
Coon Rapids, Minnesota, United States
Ann Arbor, Michigan, United States
Minneapolis, Minnesota, United States
Saint Paul, Minnesota, United States
Shakopee, Minnesota, United States
Willmar, Minnesota, United States
Boulder, Colorado, United States
Chesterfield, Missouri, United States
Dayton, Ohio, United States
Effingham, Illinois, United States
Saint Joseph, Missouri, United States
Greenville, Ohio, United States
Bethlehem, Pennsylvania, United States
Springfield, Illinois, United States
Lowell, Massachusetts, United States
Portland, Oregon, United States
Springfield, Illinois, United States
San Antonio, Texas, United States
Honolulu, Hawaii, United States
Minneapolis, Minnesota, United States
Aurora, Colorado, United States
Birmingham, Alabama, United States
Scottsdale, Arizona, United States
Sacramento, California, United States
Washington, District Of Columbia, United States
Honolulu, Hawaii, United States
Columbia, Missouri, United States
Saint Louis, Missouri, United States
New York, New York, United States
Chapel Hill, North Carolina, United States
Lexington, Kentucky, United States
Kettering, Ohio, United States
Allentown, Pennsylvania, United States
Auburn, Washington, United States
Centralia, Washington, United States
Puyallup, Washington, United States
Provo, Utah, United States
Wyoming, Michigan, United States
Cape Girardeau, Missouri, United States
Honolulu, Hawaii, United States
Coos Bay, Oregon, United States
Washington, District Of Columbia, United States
Denver, Colorado, United States
Englewood, Colorado, United States
New Orleans, Louisiana, United States
Fridley, Minnesota, United States
Robbinsdale, Minnesota, United States
Saint Louis Park, Minnesota, United States
Saint Louis, Missouri, United States
San Juan, , Puerto Rico
Fort Lauderdale, Florida, United States
Grand Rapids, Michigan, United States
Stony Brook, New York, United States
Houston, Texas, United States
Gainesville, Florida, United States
Detroit, Michigan, United States
Saint Louis, Missouri, United States
Marshfield, Wisconsin, United States
Honolulu, Hawaii, United States
Portland, Oregon, United States
Decatur, Illinois, United States
Ottawa, Illinois, United States
Peoria, Illinois, United States
Billings, Montana, United States
Butte, Montana, United States
Missoula, Montana, United States
Galesburg, Illinois, United States
Lansing, Michigan, United States
Warren, Michigan, United States
Anchorage, Alaska, United States
Los Angeles, California, United States
Reed City, Michigan, United States
Cape Girardeau, Missouri, United States
Peru, Illinois, United States
Adrian, Michigan, United States
Monroe, Michigan, United States
Pontiac, Michigan, United States
Maplewood, Minnesota, United States
Maplewood, Minnesota, United States
Stillwater, Minnesota, United States
Great Falls, Montana, United States
Findlay, Ohio, United States
Toledo, Ohio, United States
Spartanburg, South Carolina, United States
Kalamazoo, Michigan, United States
Burbank, California, United States
'Aiea, Hawaii, United States
Honolulu, Hawaii, United States
Honolulu, Hawaii, United States
Honolulu, Hawaii, United States
Alton, Illinois, United States
Galesburg, Illinois, United States
Richmond, Indiana, United States
Kansas City, Kansas, United States
New Orleans, Louisiana, United States
Battle Creek, Michigan, United States
Grand Rapids, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Saginaw, Michigan, United States
Saint Joseph, Michigan, United States
Woodbury, Minnesota, United States
Joplin, Missouri, United States
Springfield, Missouri, United States
Springfield, Missouri, United States
Billings, Montana, United States
Billings, Montana, United States
Missoula, Montana, United States
Boardman, Ohio, United States
Dayton, Ohio, United States
Franklin, Ohio, United States
Toledo, Ohio, United States
Troy, Ohio, United States
Warren, Ohio, United States
Youngstown, Ohio, United States
East Stroudsburg, Pennsylvania, United States
American Fork, Utah, United States
Cedar City, Utah, United States
Murray, Utah, United States
Salt Lake City, Utah, United States
Tacoma, Washington, United States
Vancouver, Washington, United States
Minocqua, Wisconsin, United States
Oconomowoc, Wisconsin, United States
Rice Lake, Wisconsin, United States
Waukesha, Wisconsin, United States
Weston, Wisconsin, United States
Kettering, Ohio, United States
Aurora, Colorado, United States
Denver, Colorado, United States
Wheat Ridge, Colorado, United States
Springfield, Ohio, United States
Bellingham, Washington, United States
Seattle, Washington, United States
Seattle, Washington, United States
Livonia, Michigan, United States
San Antonio, Texas, United States
Kennewick, Washington, United States
Sedro Woolley, Washington, United States
Kailua, Hawaii, United States
Clackamas, Oregon, United States
Newberg, Oregon, United States
New Ulm, Minnesota, United States
Boise, Idaho, United States
Denver, Colorado, United States
Denver, Colorado, United States
Saint Joseph, Michigan, United States
Grand Junction, Colorado, United States
Canton, Illinois, United States
Carthage, Illinois, United States
Eureka, Illinois, United States
Kewanee, Illinois, United States
Macomb, Illinois, United States
Peru, Illinois, United States
Princeton, Illinois, United States
New Orleans, Louisiana, United States
Boise, Idaho, United States
Niles, Michigan, United States
Joplin, Missouri, United States
Walla Walla, Washington, United States
Fort Smith, Arkansas, United States
Post Falls, Idaho, United States
Bloomington, Illinois, United States
Pekin, Illinois, United States
Bolivar, Missouri, United States
Branson, Missouri, United States
Saint Louis, Missouri, United States
Bend, Oregon, United States
Saint George, Utah, United States
San Juan, , Puerto Rico
Fairbanks, Alaska, United States
Jefferson City, Missouri, United States
Oklahoma City, Oklahoma, United States
Longview, Washington, United States
Honolulu, Hawaii, United States
Lihue, Hawaii, United States
Fruitland, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Twin Falls, Idaho, United States
Rolla, Missouri, United States
Rolla, Missouri, United States
Elmira, New York, United States
Edmonds, Washington, United States
Everett, Washington, United States
Issaquah, Washington, United States
Lacey, Washington, United States
New Richmond, Wisconsin, United States
Springfield, Illinois, United States
Springfield, Ohio, United States
Anchorage, Alaska, United States
Great Falls, Montana, United States
Caldwell, Idaho, United States
Coeur D'alene, Idaho, United States
Emmett, Idaho, United States
Meridian, Idaho, United States
Nampa, Idaho, United States
Sandpoint, Idaho, United States
Garden City, Kansas, United States
Great Bend, Kansas, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Caro, Michigan, United States
Chelsea, Michigan, United States
Clarkston, Michigan, United States
Clarkston, Michigan, United States
East China Township, Michigan, United States
Flint, Michigan, United States
Flint, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Livonia, Michigan, United States
Macomb, Michigan, United States
Macomb, Michigan, United States
Marlette, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Pontiac, Michigan, United States
Rochester Hills, Michigan, United States
Saginaw, Michigan, United States
Sterling Heights, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
Warren, Michigan, United States
West Branch, Michigan, United States
Ypsilanti, Michigan, United States
Minneapolis, Minnesota, United States
Anaconda, Montana, United States
Paramus, New Jersey, United States
Westwood, New Jersey, United States
Centerville, Ohio, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Cody, Wyoming, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Anchorage, Alaska, United States
Lakewood, Colorado, United States
Thornton, Colorado, United States
Commack, New York, United States
Flushing, New York, United States
Aberdeen, Washington, United States
Seattle, Washington, United States
Shelton, Washington, United States
Yelm, Washington, United States
Boulder, Colorado, United States
Denver, Colorado, United States
Englewood, Colorado, United States
Littleton, Colorado, United States
Lone Tree, Colorado, United States
Carbondale, Illinois, United States
Carterville, Illinois, United States
Centralia, Illinois, United States
Decatur, Illinois, United States
O'fallon, Illinois, United States
Swansea, Illinois, United States
Brighton, Michigan, United States
Canton, Michigan, United States
Chelsea, Michigan, United States
Ypsilanti, Michigan, United States
Maple Grove, Minnesota, United States
Wyoming, Minnesota, United States
Sainte Genevieve, Missouri, United States
Sullivan, Missouri, United States
Sunset Hills, Missouri, United States
Centerville, Ohio, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Findlay, Ohio, United States
Findlay, Ohio, United States
Franklin, Ohio, United States
Greenville, Ohio, United States
Kettering, Ohio, United States
Troy, Ohio, United States
Clackamas, Oregon, United States
Seattle, Washington, United States
Spokane Valley, Washington, United States
Spokane, Washington, United States
Spokane, Washington, United States
Cheyenne, Wyoming, United States
Montvale, New Jersey, United States
Harrison, New York, United States
Uniondale, New York, United States
Middletown, New Jersey, United States
Basking Ridge, New Jersey, United States
Denver, Colorado, United States
Baton Rouge, Louisiana, United States
Norton Shores, Michigan, United States
Monticello, Minnesota, United States
Ridgewood, New Jersey, United States
Gaffney, South Carolina, United States
Greer, South Carolina, United States
Union, South Carolina, United States
League City, Texas, United States
Riverton, Utah, United States
Gig Harbor, Washington, United States
Eau Claire, Wisconsin, United States
Honolulu, Hawaii, United States
Port Townsend, Washington, United States
'Aiea, Hawaii, United States
Mukwonago, Wisconsin, United States
'Aiea, Hawaii, United States
Waukesha, Wisconsin, United States
Overland Park, Kansas, United States
Westwood, Kansas, United States
Caguas, , Puerto Rico
Phoenix, Arizona, United States
Glen Burnie, Maryland, United States
Phoenix, Arizona, United States
Boulder, Colorado, United States
Tawas City, Michigan, United States
Perrysburg, Ohio, United States
Metairie, Louisiana, United States
Seattle, Washington, United States
Bayamon, , Puerto Rico
Beavercreek, Ohio, United States
Stevens Point, Wisconsin, United States
Bayamon, , Puerto Rico
Manati, , Puerto Rico
Springfield, Massachusetts, United States
Hazleton, Pennsylvania, United States
Metairie, Louisiana, United States
Honolulu, Hawaii, United States
Ballwin, Missouri, United States
Washington, Missouri, United States
Denver, Colorado, United States
Golden, Colorado, United States
Lafayette, Colorado, United States
Thornton, Colorado, United States
Honolulu, Hawaii, United States
Redmond, Oregon, United States
'Aiea, Hawaii, United States
Denver, Colorado, United States
Springfield, Ohio, United States
Ponce, , Puerto Rico
Centennial, Colorado, United States
Denver, Colorado, United States
Englewood, Colorado, United States
Dixon, Illinois, United States
Washington, Illinois, United States
Farmington, Missouri, United States
Englewood, Colorado, United States
Burnsville, Minnesota, United States
Hillsborough, North Carolina, United States
San Juan, , Puerto Rico
Bozeman, Montana, United States
Cambridge, Minnesota, United States
Princeton, Minnesota, United States
'Ewa Beach, Hawaii, United States
Honolulu, Hawaii, United States
Kahului, Hawaii, United States
Kalamazoo, Michigan, United States
Tamuning, , Guam
Paramus, New Jersey, United States
Melrose Park, Illinois, United States
Spartanburg, South Carolina, United States
Spartanburg, South Carolina, United States
Missoula, Montana, United States
Charleston, South Carolina, United States
Greeley, Colorado, United States
'Aiea, Hawaii, United States
Nampa, Idaho, United States
Alton, Illinois, United States
Springfield, Illinois, United States
Perrysburg, Ohio, United States
Kalispell, Montana, United States
Lebanon, New Hampshire, United States
Wyoming, Michigan, United States
Grand Rapids, Michigan, United States
Muskegon, Michigan, United States
Troy, Ohio, United States
Nampa, Idaho, United States
Pontiac, Michigan, United States
Ann Arbor, Michigan, United States
Brighton, Michigan, United States
Chelsea, Michigan, United States
Canton, Michigan, United States
Minocqua, Wisconsin, United States
Columbia, Missouri, United States
Sunset Hills, Missouri, United States
Niles, Michigan, United States
Reed City, Michigan, United States
Saint Joseph, Michigan, United States
Lansing, Michigan, United States
Grand Rapids, Michigan, United States
Loveland, Colorado, United States
Saint Joseph, Michigan, United States
Jefferson City, Missouri, United States
Pontiac, Michigan, United States
Ridgewood, New Jersey, United States
Dayton, Ohio, United States
Grand Rapids, Michigan, United States
Sandpoint, Idaho, United States
Baker City, Oregon, United States
Ontario, Oregon, United States
Saginaw, Michigan, United States
Tawas City, Michigan, United States
Wheat Ridge, Colorado, United States
Lafayette, Colorado, United States
Detroit, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Grosse Pointe Woods, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Metairie, Louisiana, United States
Flint, Michigan, United States
Kalamazoo, Michigan, United States
Warren, Michigan, United States
East China Township, Michigan, United States
Macomb, Michigan, United States
Warren, Michigan, United States
Denver, Colorado, United States
Grosse Pointe Woods, Michigan, United States
Rochester Hills, Michigan, United States
Mount Vernon, Illinois, United States
Rolla, Missouri, United States
Cape Girardeau, Missouri, United States
Union, South Carolina, United States
Patients applied
Trial Officials
Michael E Woods
Principal Investigator
Alliance for Clinical Trials in Oncology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials